IgA Nephropathy Overview

Save information for later
Sign Up

Learn About IgA Nephropathy

What is the definition of IgA Nephropathy?
IgA nephropathy is a kidney disorder that occurs when IgA (immunoglobulin A), a protein that helps the body fight infections, settles in the kidneys. In the early stages, IgA nephropathy has no symptoms. The first sign of this condition may be blood in the urine. End-stage kidney disease may develop. In most instances, the cause of this condition is unknown; however, certain disorders have been linked with IgA nephropathy, such as cirrhosis of the liver, celiac disease, and HIV infection. Although IgA nephropathy usually occurs in a family with no other affected members, several cases of familial IgA nephropathy have been reported. Familial IgA nephropathy is suspected to run through families in an autosomal dominant manner and is linked to genetic material on the long arm of chromosome 6 (6q22-23).
What are the alternative names for IgA Nephropathy?
  • IgA nephropathy
  • Berger disease
  • Berger's disease
  • Glomerulonephritis, IGA
  • IGAN
  • Nephritis, IGA type
Who are the top IgA Nephropathy Local Doctors?
Dr. Ali G. Gharavi
Nephrology
Dr. Ali G. Gharavi
Nephrology
622 W 168th St, 
New York, NY 
 (21.0 mi)
212-305-2436
Languages Spoken:
English
See accepted insurances

Ali Gharavi is a Nephrologist in New York, New York. Dr. Gharavi and is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. His top areas of expertise are IgA Nephropathy, Glomerulonephritis, Focal Segmental Glomerulosclerosis, Chronic Kidney Disease, and Kidney Transplant.

Dr. Gerald B. Appel
Nephrology
Dr. Gerald B. Appel
Nephrology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (21.0 mi)
212-305-9876
Languages Spoken:
English
Offers Telehealth

Gerald Appel is a Nephrologist in New York, New York. Dr. Appel and is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. His top areas of expertise are Glomerulonephritis, Membranoproliferative Glomerulonephritis, Nephrotic Syndrome, Kidney Transplant, and Nephrectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Krzysztof Kiryluk
Nephrology
Dr. Krzysztof Kiryluk
Nephrology

Trustees Of Columbia University In The City Of New York

1150 Saint Nicholas Ave, 
New York, NY 
 (21.0 mi)
212-305-4931
Languages Spoken:
English
See accepted insurances

Krzysztof Kiryluk is a Nephrologist in New York, New York. Dr. Kiryluk and is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. His top areas of expertise are IgA Nephropathy, Glomerulonephritis, Focal Segmental Glomerulosclerosis, Membranous Nephropathy, and Kidney Transplant.

View All Doctors
What are the latest IgA Nephropathy Clinical Trials?
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)
Enrollment Status: Recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment perio...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)
Enrollment Status: Recruiting
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center